Vishnukant Chaturbhuj Bhutada
#604Managing Director
60
Age
39y
Exp
38y
Tenure
7/10
Risk
🎓 B.Pharm · Gulbarga University (now Sharnbasva University), Raichur (B.Pharm)
🏛️ None
CompensationTBP
Personality
7
Open
7
Cons
4
Extr
5
Agre
3
Neur
Shilpa Medicare
Healthcare · Mid Cap
Mature Stable · Innovation-Led
About
Vishnukant Chaturbhuj Bhutada is the Managing Director of Shilpa Medicare, a Mid Cap company in the Healthcare sector with a market cap of ₹7K Cr. A Visionary leader with 39 years of experience, he is known for authority-driven decision-making and partnership seeker strategy. Demonstrates high risk appetite by aggressively investing in complex oncology research and diverse therapeutic delivery systems.
FAQ
What is Vishnukant Chaturbhuj Bhutada's leadership style?
Vishnukant Chaturbhuj Bhutada is classified as a Visionary leader. He is authority-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Vishnukant Chaturbhuj Bhutada's educational background?
Vishnukant Chaturbhuj Bhutada holds a B.Pharm from Gulbarga University (now Sharnbasva University), Raichur (B.Pharm).
Who is the CEO of Shilpa Medicare?
Vishnukant Chaturbhuj Bhutada is the Managing Director of Shilpa Medicare. He has been with the company for 38 years and in the current role for 38 years.
Leadership DNA
ArchetypeVisionary
MotivationCategory Creator
CrisisRestructurer
DecisionAuthority-Driven
GrowthPartnership Seeker
PeopleNumbers Driven
InnovationDisruptor
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Demonstrates high risk appetite by aggressively investing in complex oncology research and diverse therapeutic delivery systems.”
⚡ Crisis●●●●○
Bhutada has consistently reshaped Shilpa Medicare's portfolio by divesting non-core assets and shifting focus from low-margin APIs to high-value complex generics and oncology products.
🎯 Motivation●●●●○
He transformed Shilpa Medicare from a small API manufacturer into a global leader in oncology by pioneering complex drug development and niche therapeutic segments.
👥 People●●●○○
The company's operational culture is heavily defined by a relentless focus on R&D throughput, regulatory compliance metrics, and stringent manufacturing efficiency KPIs.
📈 Growth●●●●○
Bhutada has driven growth through strategic licensing agreements and technical collaborations with global pharma majors to bring specialized oncology products to market.
💡 Innovation●●●●○
The company focuses on high-barrier, complex niche segments like oncology and immunosuppressants, often being among the first to develop difficult-to-make generic formulations.
🏃 Pace●●●●○
As a mature player in the specialty pharmaceutical space, it follows a methodical, long-cycle R&D and regulatory approval process to build its portfolio.
🌱 Purpose●●●○○
The company emphasizes affordable access to life-saving oncology drugs while maintaining a structured ESG reporting framework focused on sustainable manufacturing.
🏷️ Brand●●●●●
The company is widely recognized in the industry for its deep technical prowess in handling complex chemical synthesis and high-potency drug development.
🤝 Customer●●●●●
Shilpa Medicare operates primarily as a B2B player, supplying Active Pharmaceutical Ingredients (APIs) and finished dosage forms to global pharmaceutical partners.
💼 Employer●●●○○
Its reputation as a specialized, technical-heavy manufacturer makes it a preferred training ground for pharmaceutical scientists and quality control professionals.
📋 Mandate
The firm must pivot towards high-value complex generics and niche oncology portfolios to break out of current stagnant growth cycles.
🏢 Culture●●●○○
Focus on R&D-intensive pharmaceutical manufacturing and specialty generics requires an experimentation-based, innovation-led structure.
Financials
Revenue FY25₹1K Cr
PAT FY25₹78 Cr
Rev CAGR 5Y4.1%
OPM15.6%
NPM6.1%
ROE3.3%
ROCE7.6%
P/E27.7
Fwd P/E17.5
P/B2.5
D/E24.3
Promoter56.7%
Institutional10.9%
Mkt Cap₹7K Cr
Compensation
To Be Published
Data being verified from audited reports
